Cargando…
Expert consensus on drug treatment of chronic subdural hematoma
Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a significant space...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607705/ https://www.ncbi.nlm.nih.gov/pubmed/34809712 http://dx.doi.org/10.1186/s41016-021-00263-z |
_version_ | 1784602614387703808 |
---|---|
author | Zhang, Jianning |
author_facet | Zhang, Jianning |
author_sort | Zhang, Jianning |
collection | PubMed |
description | Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a significant space-occupying effect. Most of the patients showed good results of surgical treatment, but still some patients had a postoperative recurrence (the recurrence rate was up to 33%). Because CSDH is often seen in the elderly, patients are weak and have many basic diseases. The risk of surgical treatment is high; serious complications and even death (the death rate is up to 32%) can often occur. The overall good prognosis rate of patients aged more than 90 years is 24%. The drug treatment can provide a safe and effective treatment for elderly patients who are weak, intolerable to surgery, or failed in surgery. Low-dose and long-term use of atorvastatin (20mg/d) is suggested for continuous treatment for at least 8 weeks, while low-dose and short-term use of dexamethasone can improve the therapeutic effect of atorvastatin on CSDH. Patients should undergo CT or MRI scanning at least one time within 2 weeks after the start of drug treatment. |
format | Online Article Text |
id | pubmed-8607705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86077052021-11-23 Expert consensus on drug treatment of chronic subdural hematoma Zhang, Jianning Chin Neurosurg J Review Chronic subdural hematoma (CSDH) is a chronic space-occupying lesion formed by blood accumulation between arachnoid and dura mater, which is usually formed in the third week after traumatic brain injury. Surgical treatment is usually the first choice for patients with CSDH having a significant space-occupying effect. Most of the patients showed good results of surgical treatment, but still some patients had a postoperative recurrence (the recurrence rate was up to 33%). Because CSDH is often seen in the elderly, patients are weak and have many basic diseases. The risk of surgical treatment is high; serious complications and even death (the death rate is up to 32%) can often occur. The overall good prognosis rate of patients aged more than 90 years is 24%. The drug treatment can provide a safe and effective treatment for elderly patients who are weak, intolerable to surgery, or failed in surgery. Low-dose and long-term use of atorvastatin (20mg/d) is suggested for continuous treatment for at least 8 weeks, while low-dose and short-term use of dexamethasone can improve the therapeutic effect of atorvastatin on CSDH. Patients should undergo CT or MRI scanning at least one time within 2 weeks after the start of drug treatment. BioMed Central 2021-11-22 /pmc/articles/PMC8607705/ /pubmed/34809712 http://dx.doi.org/10.1186/s41016-021-00263-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Zhang, Jianning Expert consensus on drug treatment of chronic subdural hematoma |
title | Expert consensus on drug treatment of chronic subdural hematoma |
title_full | Expert consensus on drug treatment of chronic subdural hematoma |
title_fullStr | Expert consensus on drug treatment of chronic subdural hematoma |
title_full_unstemmed | Expert consensus on drug treatment of chronic subdural hematoma |
title_short | Expert consensus on drug treatment of chronic subdural hematoma |
title_sort | expert consensus on drug treatment of chronic subdural hematoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607705/ https://www.ncbi.nlm.nih.gov/pubmed/34809712 http://dx.doi.org/10.1186/s41016-021-00263-z |
work_keys_str_mv | AT zhangjianning expertconsensusondrugtreatmentofchronicsubduralhematoma AT expertconsensusondrugtreatmentofchronicsubduralhematoma |